Evidence and clinical implications of target antigen changes and reassessment after ADC therapy in solid tumors
- 1Graduate School, Heilongjiang University of Chinese Medicine
- 2The First Affiliated Hospital of Heilongjiang University of Chinese Medicine
Abstract
There is growing interest in whether target antigens change after antibody–drug conjugate (ADC) therapy and how well previous test results reflect the current tumor state. Several studies have reported decreased, unchanged, or increased antigen expression after treatment. These findings are often influenced by the timing and site of sampling and the variables measured, and their meaning needs to be interpreted in the context of the specific drug and treatment setting. This review examines the evidence for post-treatment target antigen reassessment using HER2, FRα, TROP2, Nectin-4, HER3, and CLDN18.2 as representative targets. It draws on studies of patient specimens and ADC mechanisms of action to discuss the relationships between antigen changes, drug sensitivity, biomarker classification, and subsequent treatment selection. Reassessment after treatment can update previous test information and provide clues to ADC response and resistance. Reduced antigen expression may affect drug recognition and delivery. Disease progression despite retained expression suggests that antibody binding, intracellular processing, and payload sensitivity also need to be considered. For treatments with antigen expression requirements, reassessment can provide updated biomarker information.
Related
- Iron Supplementation and Copper Homeostasis: Evidence for Potential Copper Depletion, Biomarker Challenges, and Clinical Implications
- The Bidirectional Relationship Between Rheumatoid Arthritis and Periodontitis: Current Evidence and Clinical Implications
- Dynamic Urothelial Remodeling in Diabetic Bladder Dysfunction: Disease-Course Changes, Molecular Mechanisms, and Clinical Implications
- Lipoprotein(a) and Plaque Vulnerability: Mechanistic Insights, Imaging Evidence, and Clinical Implications
- Sepsis-associated endothelial dysfunction: clinical phenotypes, biomarkers, bedside evidence, and translational implications
BibTeX
@article{wang2026evidence,
title = {{Evidence and clinical implications of target antigen changes and reassessment after ADC therapy in solid tumors}},
author = {Zhao Wang and Yunze Shi and Songjiang Liu},
journal = {Frontiers in Oncology},
year = {2026},
month = oct,
doi = {10.3389/fonc.2026.2000729},
url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.2000729/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Evidence and clinical implications of target antigen changes and reassessment after ADC therapy in solid tumors
AU - Zhao Wang
AU - Yunze Shi
AU - Songjiang Liu
PY - 2026
DA - 2026/10/19
JO - Frontiers in Oncology
DO - 10.3389/fonc.2026.2000729
UR - https://www.frontiersin.org/articles/10.3389/fonc.2026.2000729/full
AB - There is growing interest in whether target antigens change after antibody–drug conjugate (ADC) therapy and how well previous test results reflect the current tumor state. Several studies have reported decreased, unchanged, or increased antigen expression after treatment. These findings are often influenced by the timing and site of sampling and the variables measured, and their meaning needs to be interpreted in the context of the specific drug and treatment setting. This review examines the evidence for post-treatment target antigen reassessment using HER2, FRα, TROP2, Nectin-4, HER3, and CLDN18.2 as representative targets. It draws on studies of patient specimens and ADC mechanisms of action to discuss the relationships between antigen changes, drug sensitivity, biomarker classification, and subsequent treatment selection. Reassessment after treatment can update previous test information and provide clues to ADC response and resistance. Reduced antigen expression may affect drug recognition and delivery. Disease progression despite retained expression suggests that antibody binding, intracellular processing, and payload sensitivity also need to be considered. For treatments with antigen expression requirements, reassessment can provide updated biomarker information.
SN - 2234-943X
ER -